
Talaris Therapeutics (TALS) P/E Ratio
P/E Ratio as of Dec 15, 2025: -13.97
Average-13.97
Median-13.97
Minimum-13.97
Maximum-13.97
-13.97
0.00 (0.00%)past month
The P/E ratio for Talaris Therapeutics (TALS) is -13.97 as of Dec 15, 2025. This represents a increase of 78.19% compared to its 12-month average P/E ratio of -7.84. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Talaris Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Talaris Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Talaris Therapeutics to industry peers.
Talaris Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Talaris Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Talaris Therapeutics to industry peers.
Talaris Therapeutics (TALS) P/E Ratio Insights
See Talaris Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Talaris Therapeutics (TALS)
Order type
Buy in
Order amount
Est. shares
0 shares
Talaris Therapeutics (TALS) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | — | -13.97 |
| Nov 3, 2025 | — | -13.97 |
| Oct 1, 2025 | $47.86 | -13.93 |
| Sep 2, 2025 | $23.57 | -6.86 |
| Aug 1, 2025 | $21.76 | -6.76 |
| Jul 1, 2025 | $15.83 | -4.92 |
| Jun 2, 2025 | $17.11 | -5.32 |
| May 1, 2025 | $17.85 | -6.20 |
| Apr 1, 2025 | $14.24 | -4.95 |
| Mar 3, 2025 | $12.33 | -4.37 |
| Feb 3, 2025 | $15.54 | -5.51 |
| Jan 2, 2025 | $20.64 | -7.31 |
Talaris Therapeutics (TALS) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -13.97 | +94.30% |
| 2024 | -7.19 | +310.86% |
| 2023 | -1.75 | +548.15% |
| 2022 | -0.27 | -94.74% |
| 2021 | -5.13 | — |
FAQs About Talaris Therapeutics (TALS) P/E ratio
The latest P/E ratio of Talaris Therapeutics (TALS) is -13.97, as of Dec 15, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Talaris Therapeutics’s last 12-month average P/E ratio is -7.84, compared to its current P/E ratio of -13.97. This reflects a increase of 78.19%.
Talaris Therapeutics’s current P/E ratio of -13.97 is higher than its last 12-month average P/E of -7.84. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Talaris Therapeutics’s average P/E ratio over the last 3 years is -4.31. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Talaris Therapeutics’s average P/E ratio over the last 5 years is -3.34. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.